Medical Care
Global Influenza Antiviral Drugs Market Research Report 2025
- Jul 08, 25
- ID: 347744
- Pages: 90
- Figures: 89
- Views: 1
The global market for Influenza Antiviral Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Influenza Antiviral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza Antiviral Drugs.
The Influenza Antiviral Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Influenza Antiviral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Influenza Antiviral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Boehringer Ingelheim
Merck
Novartis
Beximco Pharmaceuticals
Pfizer
Roche
Johnson & Johnson
Sanofi
Cipla Limited
Natco Pharma
Seqirus
Adamas Pharmaceuticals, Inc.
Teva Pharmaceuticals
Daiichi Sankyo Company
Segment by Type
Oseltamivir
Zanamivir
Peramivir
Adamantanes
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Pharmacies
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Influenza Antiviral Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Influenza Antiviral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza Antiviral Drugs.
The Influenza Antiviral Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Influenza Antiviral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Influenza Antiviral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Boehringer Ingelheim
Merck
Novartis
Beximco Pharmaceuticals
Pfizer
Roche
Johnson & Johnson
Sanofi
Cipla Limited
Natco Pharma
Seqirus
Adamas Pharmaceuticals, Inc.
Teva Pharmaceuticals
Daiichi Sankyo Company
Segment by Type
Oseltamivir
Zanamivir
Peramivir
Adamantanes
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Pharmacies
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Influenza Antiviral Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Influenza Antiviral Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oseltamivir
1.2.3 Zanamivir
1.2.4 Peramivir
1.2.5 Adamantanes
1.2.6 Others
1.3 Market by Application
1.3.1 Global Influenza Antiviral Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Pharmacies
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Influenza Antiviral Drugs Market Perspective (2020-2031)
2.2 Global Influenza Antiviral Drugs Growth Trends by Region
2.2.1 Global Influenza Antiviral Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Influenza Antiviral Drugs Historic Market Size by Region (2020-2025)
2.2.3 Influenza Antiviral Drugs Forecasted Market Size by Region (2026-2031)
2.3 Influenza Antiviral Drugs Market Dynamics
2.3.1 Influenza Antiviral Drugs Industry Trends
2.3.2 Influenza Antiviral Drugs Market Drivers
2.3.3 Influenza Antiviral Drugs Market Challenges
2.3.4 Influenza Antiviral Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Influenza Antiviral Drugs Players by Revenue
3.1.1 Global Top Influenza Antiviral Drugs Players by Revenue (2020-2025)
3.1.2 Global Influenza Antiviral Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Influenza Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Influenza Antiviral Drugs Revenue
3.4 Global Influenza Antiviral Drugs Market Concentration Ratio
3.4.1 Global Influenza Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Influenza Antiviral Drugs Revenue in 2024
3.5 Global Key Players of Influenza Antiviral Drugs Head office and Area Served
3.6 Global Key Players of Influenza Antiviral Drugs, Product and Application
3.7 Global Key Players of Influenza Antiviral Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Influenza Antiviral Drugs Breakdown Data by Type
4.1 Global Influenza Antiviral Drugs Historic Market Size by Type (2020-2025)
4.2 Global Influenza Antiviral Drugs Forecasted Market Size by Type (2026-2031)
5 Influenza Antiviral Drugs Breakdown Data by Application
5.1 Global Influenza Antiviral Drugs Historic Market Size by Application (2020-2025)
5.2 Global Influenza Antiviral Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Influenza Antiviral Drugs Market Size (2020-2031)
6.2 North America Influenza Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Influenza Antiviral Drugs Market Size by Country (2020-2025)
6.4 North America Influenza Antiviral Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Influenza Antiviral Drugs Market Size (2020-2031)
7.2 Europe Influenza Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Influenza Antiviral Drugs Market Size by Country (2020-2025)
7.4 Europe Influenza Antiviral Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Influenza Antiviral Drugs Market Size (2020-2031)
8.2 Asia-Pacific Influenza Antiviral Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Influenza Antiviral Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Influenza Antiviral Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Influenza Antiviral Drugs Market Size (2020-2031)
9.2 Latin America Influenza Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Influenza Antiviral Drugs Market Size by Country (2020-2025)
9.4 Latin America Influenza Antiviral Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Influenza Antiviral Drugs Market Size (2020-2031)
10.2 Middle East & Africa Influenza Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Influenza Antiviral Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Influenza Antiviral Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Influenza Antiviral Drugs Introduction
11.1.4 GSK Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.1.5 GSK Recent Development
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Details
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Influenza Antiviral Drugs Introduction
11.2.4 Boehringer Ingelheim Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.2.5 Boehringer Ingelheim Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Influenza Antiviral Drugs Introduction
11.3.4 Merck Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.3.5 Merck Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Influenza Antiviral Drugs Introduction
11.4.4 Novartis Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.4.5 Novartis Recent Development
11.5 Beximco Pharmaceuticals
11.5.1 Beximco Pharmaceuticals Company Details
11.5.2 Beximco Pharmaceuticals Business Overview
11.5.3 Beximco Pharmaceuticals Influenza Antiviral Drugs Introduction
11.5.4 Beximco Pharmaceuticals Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.5.5 Beximco Pharmaceuticals Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Influenza Antiviral Drugs Introduction
11.6.4 Pfizer Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.6.5 Pfizer Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Influenza Antiviral Drugs Introduction
11.7.4 Roche Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.7.5 Roche Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Details
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Influenza Antiviral Drugs Introduction
11.8.4 Johnson & Johnson Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.8.5 Johnson & Johnson Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Influenza Antiviral Drugs Introduction
11.9.4 Sanofi Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.9.5 Sanofi Recent Development
11.10 Cipla Limited
11.10.1 Cipla Limited Company Details
11.10.2 Cipla Limited Business Overview
11.10.3 Cipla Limited Influenza Antiviral Drugs Introduction
11.10.4 Cipla Limited Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.10.5 Cipla Limited Recent Development
11.11 Natco Pharma
11.11.1 Natco Pharma Company Details
11.11.2 Natco Pharma Business Overview
11.11.3 Natco Pharma Influenza Antiviral Drugs Introduction
11.11.4 Natco Pharma Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.11.5 Natco Pharma Recent Development
11.12 Seqirus
11.12.1 Seqirus Company Details
11.12.2 Seqirus Business Overview
11.12.3 Seqirus Influenza Antiviral Drugs Introduction
11.12.4 Seqirus Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.12.5 Seqirus Recent Development
11.13 Adamas Pharmaceuticals, Inc.
11.13.1 Adamas Pharmaceuticals, Inc. Company Details
11.13.2 Adamas Pharmaceuticals, Inc. Business Overview
11.13.3 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Introduction
11.13.4 Adamas Pharmaceuticals, Inc. Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.13.5 Adamas Pharmaceuticals, Inc. Recent Development
11.14 Teva Pharmaceuticals
11.14.1 Teva Pharmaceuticals Company Details
11.14.2 Teva Pharmaceuticals Business Overview
11.14.3 Teva Pharmaceuticals Influenza Antiviral Drugs Introduction
11.14.4 Teva Pharmaceuticals Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.14.5 Teva Pharmaceuticals Recent Development
11.15 Daiichi Sankyo Company
11.15.1 Daiichi Sankyo Company Company Details
11.15.2 Daiichi Sankyo Company Business Overview
11.15.3 Daiichi Sankyo Company Influenza Antiviral Drugs Introduction
11.15.4 Daiichi Sankyo Company Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.15.5 Daiichi Sankyo Company Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Influenza Antiviral Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oseltamivir
1.2.3 Zanamivir
1.2.4 Peramivir
1.2.5 Adamantanes
1.2.6 Others
1.3 Market by Application
1.3.1 Global Influenza Antiviral Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Pharmacies
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Influenza Antiviral Drugs Market Perspective (2020-2031)
2.2 Global Influenza Antiviral Drugs Growth Trends by Region
2.2.1 Global Influenza Antiviral Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Influenza Antiviral Drugs Historic Market Size by Region (2020-2025)
2.2.3 Influenza Antiviral Drugs Forecasted Market Size by Region (2026-2031)
2.3 Influenza Antiviral Drugs Market Dynamics
2.3.1 Influenza Antiviral Drugs Industry Trends
2.3.2 Influenza Antiviral Drugs Market Drivers
2.3.3 Influenza Antiviral Drugs Market Challenges
2.3.4 Influenza Antiviral Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Influenza Antiviral Drugs Players by Revenue
3.1.1 Global Top Influenza Antiviral Drugs Players by Revenue (2020-2025)
3.1.2 Global Influenza Antiviral Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Influenza Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Influenza Antiviral Drugs Revenue
3.4 Global Influenza Antiviral Drugs Market Concentration Ratio
3.4.1 Global Influenza Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Influenza Antiviral Drugs Revenue in 2024
3.5 Global Key Players of Influenza Antiviral Drugs Head office and Area Served
3.6 Global Key Players of Influenza Antiviral Drugs, Product and Application
3.7 Global Key Players of Influenza Antiviral Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Influenza Antiviral Drugs Breakdown Data by Type
4.1 Global Influenza Antiviral Drugs Historic Market Size by Type (2020-2025)
4.2 Global Influenza Antiviral Drugs Forecasted Market Size by Type (2026-2031)
5 Influenza Antiviral Drugs Breakdown Data by Application
5.1 Global Influenza Antiviral Drugs Historic Market Size by Application (2020-2025)
5.2 Global Influenza Antiviral Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Influenza Antiviral Drugs Market Size (2020-2031)
6.2 North America Influenza Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Influenza Antiviral Drugs Market Size by Country (2020-2025)
6.4 North America Influenza Antiviral Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Influenza Antiviral Drugs Market Size (2020-2031)
7.2 Europe Influenza Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Influenza Antiviral Drugs Market Size by Country (2020-2025)
7.4 Europe Influenza Antiviral Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Influenza Antiviral Drugs Market Size (2020-2031)
8.2 Asia-Pacific Influenza Antiviral Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Influenza Antiviral Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Influenza Antiviral Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Influenza Antiviral Drugs Market Size (2020-2031)
9.2 Latin America Influenza Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Influenza Antiviral Drugs Market Size by Country (2020-2025)
9.4 Latin America Influenza Antiviral Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Influenza Antiviral Drugs Market Size (2020-2031)
10.2 Middle East & Africa Influenza Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Influenza Antiviral Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Influenza Antiviral Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Influenza Antiviral Drugs Introduction
11.1.4 GSK Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.1.5 GSK Recent Development
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Details
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Influenza Antiviral Drugs Introduction
11.2.4 Boehringer Ingelheim Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.2.5 Boehringer Ingelheim Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Influenza Antiviral Drugs Introduction
11.3.4 Merck Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.3.5 Merck Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Influenza Antiviral Drugs Introduction
11.4.4 Novartis Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.4.5 Novartis Recent Development
11.5 Beximco Pharmaceuticals
11.5.1 Beximco Pharmaceuticals Company Details
11.5.2 Beximco Pharmaceuticals Business Overview
11.5.3 Beximco Pharmaceuticals Influenza Antiviral Drugs Introduction
11.5.4 Beximco Pharmaceuticals Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.5.5 Beximco Pharmaceuticals Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Influenza Antiviral Drugs Introduction
11.6.4 Pfizer Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.6.5 Pfizer Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Influenza Antiviral Drugs Introduction
11.7.4 Roche Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.7.5 Roche Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Details
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Influenza Antiviral Drugs Introduction
11.8.4 Johnson & Johnson Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.8.5 Johnson & Johnson Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Influenza Antiviral Drugs Introduction
11.9.4 Sanofi Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.9.5 Sanofi Recent Development
11.10 Cipla Limited
11.10.1 Cipla Limited Company Details
11.10.2 Cipla Limited Business Overview
11.10.3 Cipla Limited Influenza Antiviral Drugs Introduction
11.10.4 Cipla Limited Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.10.5 Cipla Limited Recent Development
11.11 Natco Pharma
11.11.1 Natco Pharma Company Details
11.11.2 Natco Pharma Business Overview
11.11.3 Natco Pharma Influenza Antiviral Drugs Introduction
11.11.4 Natco Pharma Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.11.5 Natco Pharma Recent Development
11.12 Seqirus
11.12.1 Seqirus Company Details
11.12.2 Seqirus Business Overview
11.12.3 Seqirus Influenza Antiviral Drugs Introduction
11.12.4 Seqirus Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.12.5 Seqirus Recent Development
11.13 Adamas Pharmaceuticals, Inc.
11.13.1 Adamas Pharmaceuticals, Inc. Company Details
11.13.2 Adamas Pharmaceuticals, Inc. Business Overview
11.13.3 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Introduction
11.13.4 Adamas Pharmaceuticals, Inc. Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.13.5 Adamas Pharmaceuticals, Inc. Recent Development
11.14 Teva Pharmaceuticals
11.14.1 Teva Pharmaceuticals Company Details
11.14.2 Teva Pharmaceuticals Business Overview
11.14.3 Teva Pharmaceuticals Influenza Antiviral Drugs Introduction
11.14.4 Teva Pharmaceuticals Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.14.5 Teva Pharmaceuticals Recent Development
11.15 Daiichi Sankyo Company
11.15.1 Daiichi Sankyo Company Company Details
11.15.2 Daiichi Sankyo Company Business Overview
11.15.3 Daiichi Sankyo Company Influenza Antiviral Drugs Introduction
11.15.4 Daiichi Sankyo Company Revenue in Influenza Antiviral Drugs Business (2020-2025)
11.15.5 Daiichi Sankyo Company Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Influenza Antiviral Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oseltamivir
Table 3. Key Players of Zanamivir
Table 4. Key Players of Peramivir
Table 5. Key Players of Adamantanes
Table 6. Key Players of Others
Table 7. Global Influenza Antiviral Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Influenza Antiviral Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Influenza Antiviral Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Influenza Antiviral Drugs Market Share by Region (2020-2025)
Table 11. Global Influenza Antiviral Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Influenza Antiviral Drugs Market Share by Region (2026-2031)
Table 13. Influenza Antiviral Drugs Market Trends
Table 14. Influenza Antiviral Drugs Market Drivers
Table 15. Influenza Antiviral Drugs Market Challenges
Table 16. Influenza Antiviral Drugs Market Restraints
Table 17. Global Influenza Antiviral Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Influenza Antiviral Drugs Market Share by Players (2020-2025)
Table 19. Global Top Influenza Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Antiviral Drugs as of 2024)
Table 20. Ranking of Global Top Influenza Antiviral Drugs Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Influenza Antiviral Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Influenza Antiviral Drugs, Headquarters and Area Served
Table 23. Global Key Players of Influenza Antiviral Drugs, Product and Application
Table 24. Global Key Players of Influenza Antiviral Drugs, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Influenza Antiviral Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Influenza Antiviral Drugs Revenue Market Share by Type (2020-2025)
Table 28. Global Influenza Antiviral Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Influenza Antiviral Drugs Revenue Market Share by Type (2026-2031)
Table 30. Global Influenza Antiviral Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Influenza Antiviral Drugs Revenue Market Share by Application (2020-2025)
Table 32. Global Influenza Antiviral Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Influenza Antiviral Drugs Revenue Market Share by Application (2026-2031)
Table 34. North America Influenza Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Influenza Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Influenza Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Influenza Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Influenza Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Influenza Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Influenza Antiviral Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Influenza Antiviral Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Influenza Antiviral Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Influenza Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Influenza Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Influenza Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Influenza Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Influenza Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Influenza Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 49. GSK Company Details
Table 50. GSK Business Overview
Table 51. GSK Influenza Antiviral Drugs Product
Table 52. GSK Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 53. GSK Recent Development
Table 54. Boehringer Ingelheim Company Details
Table 55. Boehringer Ingelheim Business Overview
Table 56. Boehringer Ingelheim Influenza Antiviral Drugs Product
Table 57. Boehringer Ingelheim Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 58. Boehringer Ingelheim Recent Development
Table 59. Merck Company Details
Table 60. Merck Business Overview
Table 61. Merck Influenza Antiviral Drugs Product
Table 62. Merck Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 63. Merck Recent Development
Table 64. Novartis Company Details
Table 65. Novartis Business Overview
Table 66. Novartis Influenza Antiviral Drugs Product
Table 67. Novartis Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 68. Novartis Recent Development
Table 69. Beximco Pharmaceuticals Company Details
Table 70. Beximco Pharmaceuticals Business Overview
Table 71. Beximco Pharmaceuticals Influenza Antiviral Drugs Product
Table 72. Beximco Pharmaceuticals Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 73. Beximco Pharmaceuticals Recent Development
Table 74. Pfizer Company Details
Table 75. Pfizer Business Overview
Table 76. Pfizer Influenza Antiviral Drugs Product
Table 77. Pfizer Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 78. Pfizer Recent Development
Table 79. Roche Company Details
Table 80. Roche Business Overview
Table 81. Roche Influenza Antiviral Drugs Product
Table 82. Roche Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 83. Roche Recent Development
Table 84. Johnson & Johnson Company Details
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Influenza Antiviral Drugs Product
Table 87. Johnson & Johnson Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 88. Johnson & Johnson Recent Development
Table 89. Sanofi Company Details
Table 90. Sanofi Business Overview
Table 91. Sanofi Influenza Antiviral Drugs Product
Table 92. Sanofi Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 93. Sanofi Recent Development
Table 94. Cipla Limited Company Details
Table 95. Cipla Limited Business Overview
Table 96. Cipla Limited Influenza Antiviral Drugs Product
Table 97. Cipla Limited Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 98. Cipla Limited Recent Development
Table 99. Natco Pharma Company Details
Table 100. Natco Pharma Business Overview
Table 101. Natco Pharma Influenza Antiviral Drugs Product
Table 102. Natco Pharma Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 103. Natco Pharma Recent Development
Table 104. Seqirus Company Details
Table 105. Seqirus Business Overview
Table 106. Seqirus Influenza Antiviral Drugs Product
Table 107. Seqirus Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 108. Seqirus Recent Development
Table 109. Adamas Pharmaceuticals, Inc. Company Details
Table 110. Adamas Pharmaceuticals, Inc. Business Overview
Table 111. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Product
Table 112. Adamas Pharmaceuticals, Inc. Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 113. Adamas Pharmaceuticals, Inc. Recent Development
Table 114. Teva Pharmaceuticals Company Details
Table 115. Teva Pharmaceuticals Business Overview
Table 116. Teva Pharmaceuticals Influenza Antiviral Drugs Product
Table 117. Teva Pharmaceuticals Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 118. Teva Pharmaceuticals Recent Development
Table 119. Daiichi Sankyo Company Company Details
Table 120. Daiichi Sankyo Company Business Overview
Table 121. Daiichi Sankyo Company Influenza Antiviral Drugs Product
Table 122. Daiichi Sankyo Company Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 123. Daiichi Sankyo Company Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
Table 127. Authors List of This Report
List of Figures
Figure 1. Influenza Antiviral Drugs Picture
Figure 2. Global Influenza Antiviral Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Influenza Antiviral Drugs Market Share by Type: 2024 VS 2031
Figure 4. Oseltamivir Features
Figure 5. Zanamivir Features
Figure 6. Peramivir Features
Figure 7. Adamantanes Features
Figure 8. Others Features
Figure 9. Global Influenza Antiviral Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Influenza Antiviral Drugs Market Share by Application: 2024 VS 2031
Figure 11. Hospitals Case Studies
Figure 12. Clinics Case Studies
Figure 13. Ambulatory Surgical Centers Case Studies
Figure 14. Pharmacies Case Studies
Figure 15. Others Case Studies
Figure 16. Influenza Antiviral Drugs Report Years Considered
Figure 17. Global Influenza Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 18. Global Influenza Antiviral Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 19. Global Influenza Antiviral Drugs Market Share by Region: 2024 VS 2031
Figure 20. Global Influenza Antiviral Drugs Market Share by Players in 2024
Figure 21. Global Top Influenza Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Antiviral Drugs as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Influenza Antiviral Drugs Revenue in 2024
Figure 23. North America Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. North America Influenza Antiviral Drugs Market Share by Country (2020-2031)
Figure 25. United States Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Canada Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Influenza Antiviral Drugs Market Share by Country (2020-2031)
Figure 29. Germany Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. France Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. U.K. Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Italy Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Russia Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Nordic Countries Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Influenza Antiviral Drugs Market Share by Region (2020-2031)
Figure 37. China Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Japan Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. South Korea Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Southeast Asia Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. India Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Australia Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Influenza Antiviral Drugs Market Share by Country (2020-2031)
Figure 45. Mexico Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Brazil Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Influenza Antiviral Drugs Market Share by Country (2020-2031)
Figure 49. Turkey Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. UAE Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. GSK Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 53. Boehringer Ingelheim Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 54. Merck Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 55. Novartis Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 56. Beximco Pharmaceuticals Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 57. Pfizer Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 58. Roche Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 59. Johnson & Johnson Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 60. Sanofi Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 61. Cipla Limited Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 62. Natco Pharma Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 63. Seqirus Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 64. Adamas Pharmaceuticals, Inc. Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 65. Teva Pharmaceuticals Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 66. Daiichi Sankyo Company Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Table 1. Global Influenza Antiviral Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oseltamivir
Table 3. Key Players of Zanamivir
Table 4. Key Players of Peramivir
Table 5. Key Players of Adamantanes
Table 6. Key Players of Others
Table 7. Global Influenza Antiviral Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Influenza Antiviral Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Influenza Antiviral Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Influenza Antiviral Drugs Market Share by Region (2020-2025)
Table 11. Global Influenza Antiviral Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Influenza Antiviral Drugs Market Share by Region (2026-2031)
Table 13. Influenza Antiviral Drugs Market Trends
Table 14. Influenza Antiviral Drugs Market Drivers
Table 15. Influenza Antiviral Drugs Market Challenges
Table 16. Influenza Antiviral Drugs Market Restraints
Table 17. Global Influenza Antiviral Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Influenza Antiviral Drugs Market Share by Players (2020-2025)
Table 19. Global Top Influenza Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Antiviral Drugs as of 2024)
Table 20. Ranking of Global Top Influenza Antiviral Drugs Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Influenza Antiviral Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Influenza Antiviral Drugs, Headquarters and Area Served
Table 23. Global Key Players of Influenza Antiviral Drugs, Product and Application
Table 24. Global Key Players of Influenza Antiviral Drugs, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Influenza Antiviral Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Influenza Antiviral Drugs Revenue Market Share by Type (2020-2025)
Table 28. Global Influenza Antiviral Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Influenza Antiviral Drugs Revenue Market Share by Type (2026-2031)
Table 30. Global Influenza Antiviral Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Influenza Antiviral Drugs Revenue Market Share by Application (2020-2025)
Table 32. Global Influenza Antiviral Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Influenza Antiviral Drugs Revenue Market Share by Application (2026-2031)
Table 34. North America Influenza Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Influenza Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Influenza Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Influenza Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Influenza Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Influenza Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Influenza Antiviral Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Influenza Antiviral Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Influenza Antiviral Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Influenza Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Influenza Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Influenza Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Influenza Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Influenza Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Influenza Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 49. GSK Company Details
Table 50. GSK Business Overview
Table 51. GSK Influenza Antiviral Drugs Product
Table 52. GSK Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 53. GSK Recent Development
Table 54. Boehringer Ingelheim Company Details
Table 55. Boehringer Ingelheim Business Overview
Table 56. Boehringer Ingelheim Influenza Antiviral Drugs Product
Table 57. Boehringer Ingelheim Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 58. Boehringer Ingelheim Recent Development
Table 59. Merck Company Details
Table 60. Merck Business Overview
Table 61. Merck Influenza Antiviral Drugs Product
Table 62. Merck Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 63. Merck Recent Development
Table 64. Novartis Company Details
Table 65. Novartis Business Overview
Table 66. Novartis Influenza Antiviral Drugs Product
Table 67. Novartis Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 68. Novartis Recent Development
Table 69. Beximco Pharmaceuticals Company Details
Table 70. Beximco Pharmaceuticals Business Overview
Table 71. Beximco Pharmaceuticals Influenza Antiviral Drugs Product
Table 72. Beximco Pharmaceuticals Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 73. Beximco Pharmaceuticals Recent Development
Table 74. Pfizer Company Details
Table 75. Pfizer Business Overview
Table 76. Pfizer Influenza Antiviral Drugs Product
Table 77. Pfizer Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 78. Pfizer Recent Development
Table 79. Roche Company Details
Table 80. Roche Business Overview
Table 81. Roche Influenza Antiviral Drugs Product
Table 82. Roche Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 83. Roche Recent Development
Table 84. Johnson & Johnson Company Details
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Influenza Antiviral Drugs Product
Table 87. Johnson & Johnson Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 88. Johnson & Johnson Recent Development
Table 89. Sanofi Company Details
Table 90. Sanofi Business Overview
Table 91. Sanofi Influenza Antiviral Drugs Product
Table 92. Sanofi Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 93. Sanofi Recent Development
Table 94. Cipla Limited Company Details
Table 95. Cipla Limited Business Overview
Table 96. Cipla Limited Influenza Antiviral Drugs Product
Table 97. Cipla Limited Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 98. Cipla Limited Recent Development
Table 99. Natco Pharma Company Details
Table 100. Natco Pharma Business Overview
Table 101. Natco Pharma Influenza Antiviral Drugs Product
Table 102. Natco Pharma Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 103. Natco Pharma Recent Development
Table 104. Seqirus Company Details
Table 105. Seqirus Business Overview
Table 106. Seqirus Influenza Antiviral Drugs Product
Table 107. Seqirus Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 108. Seqirus Recent Development
Table 109. Adamas Pharmaceuticals, Inc. Company Details
Table 110. Adamas Pharmaceuticals, Inc. Business Overview
Table 111. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Product
Table 112. Adamas Pharmaceuticals, Inc. Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 113. Adamas Pharmaceuticals, Inc. Recent Development
Table 114. Teva Pharmaceuticals Company Details
Table 115. Teva Pharmaceuticals Business Overview
Table 116. Teva Pharmaceuticals Influenza Antiviral Drugs Product
Table 117. Teva Pharmaceuticals Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 118. Teva Pharmaceuticals Recent Development
Table 119. Daiichi Sankyo Company Company Details
Table 120. Daiichi Sankyo Company Business Overview
Table 121. Daiichi Sankyo Company Influenza Antiviral Drugs Product
Table 122. Daiichi Sankyo Company Revenue in Influenza Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 123. Daiichi Sankyo Company Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
Table 127. Authors List of This Report
List of Figures
Figure 1. Influenza Antiviral Drugs Picture
Figure 2. Global Influenza Antiviral Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Influenza Antiviral Drugs Market Share by Type: 2024 VS 2031
Figure 4. Oseltamivir Features
Figure 5. Zanamivir Features
Figure 6. Peramivir Features
Figure 7. Adamantanes Features
Figure 8. Others Features
Figure 9. Global Influenza Antiviral Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Influenza Antiviral Drugs Market Share by Application: 2024 VS 2031
Figure 11. Hospitals Case Studies
Figure 12. Clinics Case Studies
Figure 13. Ambulatory Surgical Centers Case Studies
Figure 14. Pharmacies Case Studies
Figure 15. Others Case Studies
Figure 16. Influenza Antiviral Drugs Report Years Considered
Figure 17. Global Influenza Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 18. Global Influenza Antiviral Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 19. Global Influenza Antiviral Drugs Market Share by Region: 2024 VS 2031
Figure 20. Global Influenza Antiviral Drugs Market Share by Players in 2024
Figure 21. Global Top Influenza Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Antiviral Drugs as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Influenza Antiviral Drugs Revenue in 2024
Figure 23. North America Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. North America Influenza Antiviral Drugs Market Share by Country (2020-2031)
Figure 25. United States Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Canada Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Influenza Antiviral Drugs Market Share by Country (2020-2031)
Figure 29. Germany Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. France Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. U.K. Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Italy Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Russia Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Nordic Countries Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Influenza Antiviral Drugs Market Share by Region (2020-2031)
Figure 37. China Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Japan Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. South Korea Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Southeast Asia Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. India Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Australia Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Influenza Antiviral Drugs Market Share by Country (2020-2031)
Figure 45. Mexico Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Brazil Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Influenza Antiviral Drugs Market Share by Country (2020-2031)
Figure 49. Turkey Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. UAE Influenza Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. GSK Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 53. Boehringer Ingelheim Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 54. Merck Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 55. Novartis Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 56. Beximco Pharmaceuticals Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 57. Pfizer Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 58. Roche Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 59. Johnson & Johnson Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 60. Sanofi Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 61. Cipla Limited Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 62. Natco Pharma Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 63. Seqirus Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 64. Adamas Pharmaceuticals, Inc. Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 65. Teva Pharmaceuticals Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 66. Daiichi Sankyo Company Revenue Growth Rate in Influenza Antiviral Drugs Business (2020-2025)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232